Broad-spectrum antimicrobials and the treatment of serious bacterial infections: Getting it right up front

Clinical Infectious Diseases

Volumn 47, Issue SUPPL.1, 2008, Pages

  Kollef, Marin H ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM; CEFADROXIL; CEFALEXIN; CEFEPIME; CEFUROXIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; CLOXACILLIN; DAPTOMYCIN; DICLOXACILLIN; FLUCLOXACILLIN; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; NAFCILLIN; OFLOXACIN; OXACILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DEATH; DRUG SENSITIVITY; ECONOMICS; ESCHERICHIA COLI; FUNGEMIA; HOSPITALIZATION; HUMAN; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; REVIEW; RISK; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; SURVIVAL; VENTILATOR ASSOCIATED PNEUMONIA;

ANTI-BACTERIAL AGENTS; BACTERIA; BACTERIAL INFECTIONS; HUMANS; LENGTH OF STAY; TIME FACTORS;

EID: 51549114537     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/590061     Document Type: Review

References (77)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society Consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44(Suppl 2):S27-72.
2. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
3. Bodmann KF. Current guidelines for the treatment of severe pneumonia and sepsis. Chemotherapy 2005; 51:227-33.
4. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-99.
5. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007; 44:159-77.
6. Micek ST, Roubinian N, Heuring T, et al. Before-after study of a standardized hospital order set for the management of septic shock. Crit Care Med 2006; 34:2707-13.
7. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
8. Soo-Hoo GW, Wen YE, Nguyen TV, Goetz MB. Impact of clinical guidelines in the management of severe hospital-acquired pneumonia. Chest 2005; 128:2778-87.
9. Fraser A, Paul M, Almanasreh N, et al. Benefit of appropriate empirical antibiotic treatment: thirty-day mortality and duration of hospital stay. Am J Med 2006; 119:970-6.
10. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
11. Leibovici L, Shraga I, Drucker M, Konigsberger H, Samra Z, Pitlik SD. The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection. J Intern Med 1998; 244:379-86.
12. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother 2005; 49:1306-11.
13. Vallés J, Rello J, Ochagavía A, Garnacho J, Alcalá MA. Community-acquired bloodstream infection in critically ill adult patients: impact of shock and inappropriate antibiotic therapy on survival. Chest 2003; 123:1615-24.
14. Harbarth S, Garbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35.
15. Micek ST, Isakow W, Shannon W, Kollef MH. Predictors of hospital mortality for patients with severe sepsis treated with drotrecogin alfa (activated). Pharmacotherapy 2005; 25:26-34.
16. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus β-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-33.
17. Armenian SH, Singh J, Arrieta AC. Risk factors for mortality resulting from bloodstream infections in a pediatric intensive care unit. Pediatr Infect Dis J 2005; 24:309-14.
18. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-6.
19. Fluckiger U, Zimmerli W, Sax H, Frei R, Widmer AF. Clinical impact of an infectious disease service on the management of bloodstream infection. Eur J Clin Microbiol Infect Dis 2000; 19:493-500.
20. Kang CI, Kim SH, Park WB, et al. Bloodstream infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004; 48:4574-81.
21. Kang CI, Kim SH, Park WB, et al. Bloodstream infections caused by antibiotic-resistant gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005; 49:760-6.
22. Peralta G, Sánchez MB, Garrido JC, et al. Impact of antibiotic resistance and of adequate empirical antibiotic treatment in the prognosis of patients with Escherichia coli bacteraemia. J Antimicrob Chemother 2007; 60:855-63.
23. Schwaber MJ, Navon-Venezia S, Kaye KS, Ben-Ami R, Schwatrz D, Carmeli Y. Clinical and economic impact of bacteremia with extended-spectrum β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother 2006; 50:1257-62.
24. Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum β-lactamase-producing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother 2007; 51:1987-94.
25. Schramm GE, Johnson JA, Doherty JA, Micek ST, Kollef MH. Methicillin-resistant Staphylococcus aureus sterile-site infection: the importance of appropriate initial antimicrobial treatment. Crit Care Med 2006; 34:2069-74.
26. Lautenbach E, Metlay JP, Bilker WB, Edelstein PH, Fishman NO. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: the role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41:923-9.
27. Alvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996; 22:387-94.
28. Rello J, Gallego M, Mariscal D, Sonora R, Valles J. The value of routine microbial investigation in ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:196-200.
29. Kollef MH, Ward S. The influence of mini-BAL cultures on patient outcomes: implications for the antibiotic management of ventilator-associated pneumonia. Chest 1998; 113:412-20.
30. Leone M, Garcin F, Bouvenot J, et al. Ventilator-associated pneumonia: breaking the vicious circle of antibiotic overuse. Crit Care Med 2007; 35:379-85.
31. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 2005; 49:3640-5.
32. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase-producing Enterobacteriaceae. Arch Intern Med 2005; 165:1375-80.
33. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34:1589-96.
34. Luna CM, Vujacich P, Niederman MS, et al. Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia. Chest 1997; 111:676-85.
35. Iregui M, Ward S, Sherman G, Fraser VJ, Kollef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-8.
36. Kollef MH. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63:2157-68.
37. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:1040-8.
38. Kollef MH, Ward S, Sherman G, et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit Care Med 2000; 28:3456-64.
39. Mitchell DH, Howden BP. Diagnosis and management of Staphylococcus aureus bacteremia. Intern Med J 2005; 35(Suppl 2):S17-24.
40. Fowler VG Jr, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006; 355:653-65.
41. Ruotsalainen E, Järvinen A, Koivula I, et al. Levofloxacin does not decrease mortality in Staphylococcus aureus bacteraemia when added to the standard treatment: a prospective and randomized clinical trial of 381 patients. J Intern Med 2006; 259:179-90.
42. Jellison TK, McKinnon PS, Rybak MJ. Epidemiology, resistance, and outcomes of Acinetobacter baumannii bacteremia treated with imipenem-cilastatin or ampicillin-sulbactam. Pharmacotherapy 2001; 21:142-8.
43. Kuo LC, Lai CC, Liao CH, et al. Multidrug-resistant Acinetobacter baumannii bacteremia: clinical features, antimicrobial therapy, and outcome. Clin Microbiol Infect 2007; 13:196-8.
44. Zelenitsky SA, Harding GKM, Sun S, Ubhi K, Ariano RE. Treatment outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother 2003; 52:668-74.
45. Ramphal R, Ambrose PG. Extended-spectrum β-lactamases and clinical outcomes: current data. Clin Infect Dis 2006; 42(Suppl 4):S164-72.
46. Paterson DL, Ko W-C, Von Gottberg A, et al. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum β-lactamases. Clin Infect Dis 2004; 39:31-7.
47. Rodriguez-Bano J, Navarro MD, Romero L, et al. Bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43:1407-14.
48. Huang SS, Lee MH, Leu HS. Bacteremia due to extended-spectrum beta-lactamase-producing Enterobacteriaceae other than Escherichia coli and Klebsiella. J Microbiol Immunol Infect 2006; 39:496-502.
49. Cometta A, Baumgartner JD, Lew D, et al. Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients. Antimicrob Agents Chemother 1994; 38:1309-13.
50. Namias N, Harvill S, Ball S, et al. Empiric therapy of sepsis in the surgical intensive care unit with broad-spectrum antibiotics for 72 h does not lead to the emergence of resistant bacteria. J Trauma 1998; 45:887-91.
51. Geddes A, Thaler M, Schonwald S, Härkönen M, Jacobs F, Nowotny I. Levofloxacin in the empirical treatment of patients with suspected bacteraemia/sepsis: comparison with imipenem/cilastatin in an open, randomized trial. J Antimicrob Chemother 1999; 44:799-810.
52. Verwaest C. Meropenem versus imipenem/cilastatin as empirical monotherapy for serious bacterial infections in the intensive care unit. Clin Microbiol Infect 2000; 6:294-302.
53. Badaró R, Molinar F, Seas C, et al. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections. Braz J Infect Dis 2002; 6:206-18.
54. Morris MI, Villmann M. Echinocandins in the management of invasive fungal infections, part 2. Am J Health Syst Pharm 2006; 63:1813-20.
55. Shorr AF, Lazarus DR, Sherner JH, et al. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia. Crit Care Med 2007; 35:1077-83.
56. Jeu LA, Piacenti FJ, Lyakhovetskiy AG, Fung HB. Voriconazole. Clin Ther 2003; 25:1321-81.
57. Fagon JY, Rello J. Targeted antibiotic management of ventilator associated pneumonia. Clin Microbiol Infect 2006; 12(Suppl 9):17-22.
58. Kollef MH. Appropriate empiric antimicrobial therapy of nosocomial pneumonia: the role of carbapenems. Respir Care 2004; 49:1530-41.
59. Berman SJ, Fogarty CM, Fabian T, Melnick D, Lesky W. Meropenem monotherapy for the treatment of hospital-acquired pneumonia: results of a multicenter trial. J Chemother 2004; 16:362-71.
60. Colardyn F, Faulkner KL. Intravenous meropenem verses imipenem/cilastatin in the treatment of serious bacterial infections in hospitalized patients. Meropenem Serious Infection Study Group. J Antimicrob Chemother 1996; 38:523-37.
61. Hartenauer U, Kljucar S, Bender HJ, et al. Meropenem versus imipenem/cilastatin for the treatment of serious bacterial infections at ICU. Antiinfective Drugs Chemother 1997; 15:65-70.
62. Jaccard C, Troillet N, Harbarth S, Zanetti G, Aymon D, Schneider R. Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis. Antimicrob Agents Chemother 1998; 42:2966-72.
63. Torres A, Bauer TT, Leon-Gil C, et al. Treatment of severe nosocomial pneumonia: a prospective randomized comparison of intravenous ciprofloxacin with imipenem/cilastatin. Thorax 2000; 55:1033-9.
64. West M, Boulanger BR, Fogarty C, et al. Levofloxacin compared with imipenem/cilastatin followed by ciprofloxacin in adult patients with nosocomial pneumonia: a multicenter, prospective, randomized, open-label study. Clin Ther 2003; 25:485-506.
65. Alvarez-Lerma F, Serious Infection Study Group. Efficacy of meropenem as monotherapy in the treatment of ventilator-associated pneumonia. J Chemother 2001; 13:70-81.
66. Sieger B, Berman SJ, Geckler RW, Farkas SA. Empiric treatment of hospital-acquired lower respiratory tract infections with meropenem or ceftazidime with tobramycin: a randomized study. Meropenem Lower Respiratory Infection Group. Crit Care Med 1997; 25:1663-70.
67. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactam versus ceftazidime in association with amikacin for treating nosocomial pneumonia in intensive care patients: a prospective, randomized, multicenter trial. Intensive Care Med 2001; 27:493-502.
68. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH, Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25:980-92.
69. Bartoloni A, Strohmeyer M, Corti G, et al. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Drugs Exp Clin Res 1999; 25:243-52.
70. Mouton YJ, Beuscart C, Meropenem Study Group. Empirical monotherapy with meropenem in serious bacterial infections. J Antimicrob Chemother 1995; 36(Suppl A):145-56.
71. Edelstein H, Chirurgi V, Oster S, et al. A randomized trial of cefepime (BMY-28142) and ceftazidime for the treatment of pneumonia. J Antimicrob Chemother 1991; 28:569-75.
72. Fogarty CM, Cyganowski M, Paolo WA, Hom RC, Craig WA. A comparison of cefditoren pivoxil and amoxicillin/clavulanate in the treatment of community-acquired pneumonia: a multicenter, prospective, randomized, investigator-blinded, parallel group study. Clin Ther 2002; 24:1854-70.
73. Krumpe PD, Cohn S, Garreltes J, et al. Intravenous and oral mono-or combination-therapy in the treatment of severe infections: ciprofloxacin versus standard antibiotic therapy. Ciprofloxacin Study Group. J Antimicrob Chemother 1999; 43(Suppl A):117-28.
74. Kollef MH, Morrow LE, Niederman MS, et al. Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. Chest 2006; 129:1210-8.
75. Shorr AF, Micek ST, Jackson WL, Kollef MH. Economic implications of an evidence-based sepsis protocol: can we improve outcomes and lower costs? Crit Care Med 2007; 35:1257-62.
76. Berild D, Mohseni A, Diep LM, Jensenius M, Ringertz SH. Adjustment of antibiotic treatment according to the results of blood cultures leads to decreased antibiotic use and costs. J Antimicrob Chemother 2006; 57:326-30.
77. Kollef MH, Micek ST. Strategies to prevent antimicrobial resistance in the intensive care unit. Crit Care Med 2005; 33:1845-53.